Clinical Research Papers:
Ultrasound-guided percutaneous microwave ablation assisted by three-dimensional visualization operative treatment planning system and percutaneous transhepatic cholangial drainage with intraductal chilled saline perfusion for larger hepatic hilum hepatocellular (D ≥ 3 cm): preliminary results
Metrics: PDF 1822 views | HTML 2507 views | ?
Abstract
Xin Li1,*, Jie Yu1,*, Ping Liang1, Xiaoling Yu1, Zhigang Cheng1, Zhiyu Han1, Shaobo Duan1 and Jiasheng Zheng2
1Department of Interventional Ultrasound, Chinese PLA General Hospital, Beijing, 100853, China
2Minimally Intervention Therapy Center of Liver Diseases and Oncology, Beijing You An Hospital, Capital Medical University, Beijing, 100069, China
*These authors are contributed equally to this work and co-first authors
Correspondence to:
Ping Liang, email: [email protected]
Keywords: hepatic hilar hepatocellular carcinoma, ultrasound-guided percutaneous microwave ablation, three-dimensional visualization operative treatment planning system, percutaneous transhepatic cholangial drainage with intraductal chilled saline perfusion
Received: November 22, 2016 Accepted: June 02, 2017 Published: July 15, 2017
ABSTRACT
To assess the clinical efficiency of ultrasound-guided percutaneous microwave ablation (US-PMWA) assisted by three-dimensional (3D) visualization operative treatment planning system and percutaneous transhepatic cholangial drainage with intraductal chilled saline perfusion (PTCD-ICSP) for larger hepatic hilum hepatocellular carcinoma (HH-HCC) (D ≥ 3 cm). The combination therapy was performed in 14 patients from Sep 2011 to May 2017. The major outcomes for assessment were biliary duct complications, local tumor recurrence, distant recurrence and overall survival rates. Median follow-up period was 26 months. The series of 3D visualization operative treatment planning, PTCD-ICSP and US-PMWA were successfully performed and complete ablation was achieved in all cases. The mean session for one tumor was 1.0 ± 0.4. The mean ablation time for per tumor was 1805 ± 567s. The saline volume used for the PTCD-ICSP was 250–450 ml per session. The 1-, 2-, and 3-year local tumor recurrence rates were 7.1%, 14.3%, and 35.7%, the 1-, 2-, and 3-year distant recurrence rates were 0%, 14.3%, and 28.6%, and 1-, 2-, and 3-year overall survival rates were 100%, 92.9%, and 71.4%, respectively. No severe complications related to ablation occurred.
Conclusions: US-PMWA assisted by 3D visualization operative treatment planning system and PTCD-ICSP appears to be a safe, effective and innovative technique for management for larger HH-HCCs, which improved the prognosis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19275